“Pancreatic Beta-cell Protection Hot Targets & Pipeline Analysis” gives comprehensive insight on the various drugs being developed for the treatment of Pancreatic Beta-cell protection. The report covers hot targets & molecules in research for beta-cell protection in both Type-1 diabetes & Type-2 diabetes disease progression.
This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Diabetes Drug market. The report also provides strategic insights on medicines that are likely to have an impact on beta-cell protection treatment space and potentially alter standards of care in the foreseeable future.
Therapies that are presently available for diabetes focus on reducing the disease symptoms, but there is a huge unmet need for therapies that can either slow or prevent the beta cell loss as there is a rapid loss of cells in type 1 diabetes and progressive loss in type 2 diabetes patients
Currently, researchers are focusing on novel therapeutic strategies aimed at restoring, or at least preventing further loss of beta cell mass in beta cell deficit type 1 and type 2 diabetes patients as endogenous secretion of insulin is advantageous over exogenous insulin such as direct effect on hepatic (liver) glucose metabolism. Hence, it provides a tremendous opportunity for upcoming therapies specific to Beta-cell loss such as MAbs, stem cell-based, gene therapies and RNA-based therapies. These modalities may provide beta-cell protection, regeneration, mass increase with additional benefits of weight loss, triglyceride lowering and kidney protection.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook